Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

ABSTRACT:

Aims

To evaluate the safety and pharmacokinetics of naringenin in healthy adults consuming whole-orange (Citrus sinensis) extract.

Methods and methods

In a single-ascending-dose randomized crossover trial, 18 adults ingested doses of 150 mg (NAR150), 300 mg (NAR300), 600 mg (NAR600) and 900 mg (NAR900) naringenin or placebo. Each dose or placebo was followed by a wash-out period of at least 1 week. Blood safety markers were evaluated pre-dose and 24 hours post-dose. Adverse events (AEs) were recorded. Serum naringenin concentrations were measured before and over 24 hours following ingestion of placebo, NAR150 and NAR600. Four- and 24-hour serum measurements were obtained after placebo, NAR300 and NAR900 ingestion. Data were analysed using a mixed-effects linear model.

Res

SUBMITTER: Rebello CJ 

PROVIDER: S-EPMC6956701 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature